< 1 minute read
Feb. 9, 2022

Berotralstat (BCX7353): an Oral Plasma Kallikrein Inhibitor

BioCryst Kallikrein Inhibitor

oral plasma kallikrein serine protease inhibitor approved for prevention of HAE attacks from structure-based drug design berotralstat BioCryst, Birmingham, AL

twitterlinkedinprintemail

Molecules of the Month

MOTY Nominees

Molecule of the Year